In this study, we found that H1650 lung cancer cells developed resistance to erlotinib and underwent EMT phenotypic changes, which were consistent with decreased expression of the epithelial marker E-cadherin and increased expression of the mesenchymal markers vimentin. Here, VIM is linked to lung carcinoma.